The FDA has approved Fiasp (insulin aspart injection) 100 units/mL, a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes, available from Novo Nordisk, Plainsboro NJ.
Indications: Fiasp is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.
Dosage/administration: Can be dosed at the beginning of a meal or within 20 minutes after starting a meal. Individualize and adjust dosage based on route of administration, individual’s metabolic needs, blood glucose monitoring results, and glycemic control goal.
Adverse reactions: Adverse reactions include hypoglycemia, allergic reactions, hypersensitivity, injection site reactions, lipodystrophy, and weight gain.
Novo Nordisk receives FDA approval for Fiasp, a new fast-acting mealtime insulin. [news release]. Novo Nordisk, Plainsboro, NJ. September 29. 2017. http://press.novonordisk-us.com/2017-09-29-Novo-Nordisk-Receives-FDA-Approval-for-Fiasp-R-a-New-Fast-Acting-Mealtime-Insulin. Accessed October 8, 2017.
This Week's Must Reads
Must Reads in Diabetes
Testosterone Therapy to Prevent T2D in Men, Diabetes Care; ePub 2019 Mar 18; Yassin, et al
Patterns of Diabetes Screening During Office Visits, J Am Board Fam Med; 2019 Mar-Apr; Shealy, et al